Related Experiment Videos
ESAT-6 subunit vaccination against Mycobacterium tuberculosis
L Brandt1, M Elhay, I Rosenkrands
1Department of TB Immunology, Statens Serum Institut, Copenhagen, Denmark.
Infection and Immunity
|January 20, 2000
Summary
The study evaluated the early-phase tuberculosis (TB) antigen ESAT-6 as a vaccine candidate. Combining monophosphoryl lipid A (MPL) with DDA adjuvant successfully induced protective immunity against TB.
Area of Science:
- Immunology
- Vaccinology
- Microbiology
Background:
- Early-phase cell-mediated immunity in tuberculosis (TB) primarily targets the ESAT-6 antigen.
- ESAT-6 is a key antigen for immune responses in TB patients and animal models.
Purpose of the Study:
- To assess the efficacy of ESAT-6 as an experimental TB vaccine component.
- To investigate adjuvant systems for enhancing immune responses to ESAT-6.
Main Methods:
- Vaccination trials using ESAT-6 delivered with dimethyl dioctadecylammonium bromide (DDA) adjuvant.
- Evaluation of immune responses with DDA alone and in combination with monophosphoryl lipid A (MPL).
- Comparison of vaccine-induced protection against Mycobacterium tuberculosis challenge with Mycobacterium bovis BCG.
Main Results:
- DDA adjuvant effectively induced immune responses to short-term-culture filtrate and Ag85B, but not ESAT-6.
- Combining MPL with DDA significantly enhanced ESAT-6-specific T-cell responses.
- The MPL + DDA adjuvant system elicited protective immunity comparable to Mycobacterium bovis BCG.
Conclusions:
- DDA alone is insufficient for inducing robust immune responses to ESAT-6.
- The combination of MPL and DDA is a potent adjuvant system for ESAT-6-based TB vaccines.
- ESAT-6 formulated with MPL and DDA shows promise as an effective TB vaccine candidate.